Calls For COVID Patent Waivers Persist As Pooling Initiatives Plough Ahead
Patents On COVID-19 Therapeutics Have Been Accused Of Impeding International Access
Executive Summary
The formulas for various COVID-19 vaccines remain shrouded in intellectual property protections – one of many factors preventing them from being manufactured in developing nations. Those in favor of upholding IP say that scrapping patents could stifle future innovation, but their opponents believe preserving COVID-19 related IP rights is limiting access to lifesaving medical tools.
You may also be interested in...
Medicines Patent Pool Centers On Consolidation In Its New Three-Year Strategy
The Medicines Patent Pool’s new strategy could open the door to significant new opportunities for generic drug suppliers across low- and middle-income countries, as it explores its remit in new fields such as biologics, early-stage drug development and even – possibly – antimicrobial resistance.
Next-Gen Vaccine Makers Want Up-Front Discussions With US FDA To Expedite Development
Early conversations on clinical trial endpoints were particularly helpful in developing Comirnaty, a Pfizer executive said. Whether sponsors can continue to get such discussions may go a long way in determining whether a new generation of products is developed.
MPP Announces Generic Paxlovid Licences For LMICs
A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.